Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07154264 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of DZD8586 Combination in CLL/SLL (TAI-SHAN10)

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Lead sponsor: Dizal (Jiangsu) Pharmaceutical Co., Ltd. to Dizal Pharmaceuticals Site details revised at 1 of 15 sitesv4 Show 1 more changeShow less
    • Site details revised at 1 of 15 sites
  2. Site details revised at 8 of 15 sitesv3
  3. Trial status: Not Yet Recruiting to Recruiting Study sites: 0 to 15 · Start date changed from estimate of Oct 2025 to Sep 22, 2025v2 Show 2 more changesShow less
    • Study sites: 0 to 15
    • Start date changed from estimate of Oct 2025 to Sep 22, 2025
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a phase 2 study to investigate the efficacy and safety of DZD8586 in combination in participants with CLL/SLL. This study consists of two parts: Part A is the safety lead-in phase, and Part B is the dose expansion phase.
Trial Details
NCT Number NCT07154264
Lead Sponsor Dizal Pharmaceuticals
Conditions Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Enrollment 66 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov